Drugs Containing Excipient (Inactive Ingredient) ETHYLCELLULOSES

« Back to Dashboard

Branded drugs containing ETHYLCELLULOSES excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	THIOLA	tiopronin	0178-0900	ETHYLCELLULOSES
Bayer HealthCare LLC	CLARITIN-D	loratadine and pseudoephedrine sulfate	11523-4332	ETHYLCELLULOSES
STAT Rx USA LLC	WELLBUTRIN	bupropion hydrochloride	16590-246	ETHYLCELLULOSES

Generic drugs containing ETHYLCELLULOSES excipient

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	morphine sulfate	0115-1277	ETHYLCELLULOSES
Amneal Pharmaceuticals of New York LLC	fenofibric acid	0115-1324	ETHYLCELLULOSES
Amneal Pharmaceuticals of New York LLC	dexmethylphenidate hydrochloride	0115-1686	ETHYLCELLULOSES

Ethylcellulose Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 28, 2026

Ethylcellulose is a mature, specialty pharmaceutical excipient used primarily for modified-release matrices, film coating, taste masking, microencapsulation, and multiparticulate dosage forms. Its financial trajectory is likely to track low- to mid-single-digit volume growth, with higher-value growth in aqueous dispersions, controlled-release platforms, and regulatory-grade supply. The market is fragmented, and no authoritative public dataset reports global pharmaceutical ethylcellulose revenue as a standalone category.

Demand is supported by generic modified-release products, oral solid-dose development, pediatric taste masking, and manufacturing flexibility. Pricing power is strongest for compendial grades with validated supply histories and weakest for commodity-grade ethylcellulose exposed to regional competition.

What is ethylcellulose used for in pharmaceutical formulations?

Ethylcellulose is a chemically modified cellulose ether identified by CAS No. 9004-57-3. It is produced by substituting ethoxy groups for hydroxyl groups on cellulose. The polymer is water-insoluble but soluble in selected organic solvents, depending on viscosity grade and degree of substitution.

Pharmaceutical uses include:

Application	Functional role	Commercial relevance
Modified-release tablets	Hydrophobic matrix former that slows liquid penetration and drug diffusion	Core demand segment
Film coating	Moisture barrier, taste masking, and release-rate control	Important in oral solids
Multiparticulates	Coating of pellets, beads, and granules	Growing with flexible-release products
Microencapsulation	Barrier around drug particles or cores	Used in controlled release and taste masking
Hot-melt extrusion	Polymer carrier for drug dispersion	Specialized growth area
Osmotic and reservoir systems	Rate-controlling membrane component	Niche, formulation-dependent
Food and nutraceutical products	Coating and encapsulation polymer	Adjacent demand pool

Ethylcellulose does not form a conventional aqueous solution. Formulators use organic solvent systems, aqueous dispersions, or commercial pre-dispersed products. Aqueous systems reduce solvent-handling requirements and can simplify manufacturing, although they require process optimization for coalescence and coating performance.

The United States Pharmacopeia-National Formulary and European Pharmacopoeia recognize pharmaceutical ethylcellulose specifications, including identification, viscosity, loss on drying, residue on ignition, and substitution-related controls [1,2].

How large is the pharmaceutical ethylcellulose market?

A defensible standalone market size is unavailable because producers and market researchers generally aggregate ethylcellulose with broader pharmaceutical excipients, cellulose ethers, coating polymers, or controlled-release excipients.

Public market reports commonly combine several categories:

• Cellulose ethers, including hypromellose, hydroxypropyl cellulose, carboxymethylcellulose, and ethylcellulose.
• Pharmaceutical excipients, which include fillers, binders, disintegrants, lubricants, coatings, and solubilizers.
• Functional excipients, including polymers used for modified release and drug delivery.
• Film-coating materials, where ethylcellulose competes with hypromellose, polyvinyl alcohol, methacrylate copolymers, and lipid systems.

The relevant economic market is therefore narrower than the total pharmaceutical excipient market but more specialized than commodity cellulose derivatives. Ethylcellulose has a higher value per kilogram than basic cellulose fillers because customers purchase a performance specification, not simply a chemical identity.

What factors determine ethylcellulose pricing?

Pricing depends on:

1. Viscosity grade and molecular-weight distribution.
2. Pharmaceutical or food grade designation.
3. Compendial compliance.
4. Particle size and powder handling characteristics.
5. Residual solvent and impurity profile.
6. Documentation, audit history, and change-control obligations.
7. Packaging and regional logistics.
8. Whether the product is a dry polymer or a formulated aqueous dispersion.
9. Batch size and customer qualification status.

Standard ethylcellulose powder is more exposed to price competition. Aqueous dispersions and customer-specific coating systems command higher prices because they incorporate formulation know-how, process support, and qualification costs.

What is the financial trajectory for pharmaceutical ethylcellulose?

The most supportable base case is steady expansion rather than rapid growth. A reasonable planning framework is:

Scenario	Volume trajectory	Pricing trajectory	Estimated market value trend
Downside	0% to 2% annual growth	Flat to negative	Flat or low-single-digit growth
Base case	3% to 5% annual growth	0% to 2% annual growth	Approximately 3% to 7% annual growth
Upside	5% to 8% annual growth	1% to 3% annual growth	Approximately 6% to 11% annual growth

These are analytical ranges, not reported market forecasts. They reflect the product's mature status, continued use in oral solid dosage forms, and selective expansion in controlled-release technologies.

Revenue growth should come from three sources:

• Higher demand for modified-release generic and branded products.
• Conversion from solvent-based coating to aqueous ethylcellulose dispersions.
• Greater use in multiparticulates, taste masking, and complex oral delivery systems.

Margin performance is likely to diverge by product type. Commodity powder margins face raw-material and energy pressure. Qualified pharmaceutical grades and dispersion products can maintain better margins because substitution requires revalidation, stability testing, and regulatory documentation.

Which applications will drive future ethylcellulose demand?

Modified-release generic drugs

Modified-release generics remain the largest structural demand driver. Ethylcellulose is useful when a formulation requires a hydrophobic diffusion barrier or a release profile that cannot be achieved economically with a simple hydrophilic matrix.

The generic market supports recurring excipient demand because each commercial product requires ongoing manufacturing supply. However, generic pricing pressure limits the ability of drug manufacturers to absorb large excipient price increases.

Aqueous ethylcellulose dispersions

Aqueous dispersions address environmental, safety, and operational concerns associated with organic solvents. Commercial products such as Colorcon's Surelease use ethylcellulose in a preformulated dispersion system for controlled-release coating applications [3].

This segment has stronger revenue quality than unformulated powder because customers purchase a processing system. The supplier can compete through coating uniformity, plasticizer compatibility, process robustness, and technical service.

Taste masking and pediatric products

Ethylcellulose can reduce the release of bitter active ingredients in the mouth while allowing drug release after administration. Demand is linked to pediatric formulations, orally disintegrating products, and multiparticulate dosage forms.

This application is technically attractive but remains smaller than mainstream modified-release tablets. Product success depends on balancing taste masking, dissolution, drug loading, and manufacturability.

Hot-melt extrusion and advanced delivery

Ethylcellulose is used in selected hot-melt extrusion and drug-dispersion systems. Growth is possible as pharmaceutical developers adopt continuous manufacturing and advanced oral delivery technologies. The segment will remain selective because ethylcellulose has processing limitations, including thermal behavior, drug-polymer compatibility requirements, and the need to optimize plasticization.

Who are the main ethylcellulose pharmaceutical excipient suppliers?

The supplier field includes multinational excipient companies, cellulose specialists, and regional manufacturers.

Supplier or brand	Relevant offering	Competitive position
Ashland	Aqualon ethylcellulose grades	Global pharmaceutical excipient supplier with technical support
Dow	ETHOCEL ethylcellulose polymers	Established polymer platform and broad industrial reach
Colorcon	Surelease aqueous ethylcellulose dispersion	Strong position in film coating and modified-release systems
Regional cellulose-ether producers	Ethylcellulose powders and related cellulose derivatives	Price competition and regional supply
Specialty formulation suppliers	Custom dispersions, coating systems, and delivery platforms	Higher-value, application-specific competition

Supplier identity and ownership can change through divestitures, portfolio transfers, and regional distribution agreements. Pharmaceutical customers generally evaluate the legal manufacturer, manufacturing site, quality system, and regulatory documentation rather than brand name alone.

How does ethylcellulose compare with competing excipients?

Ethylcellulose competes with several polymer classes rather than with one direct substitute.

Excipient	Main advantage	Main limitation relative to ethylcellulose
Hypromellose	Strong water-based gel matrix and broad regulatory familiarity	Release mechanism differs; may not provide the same hydrophobic barrier
Polyvinyl acetate	Effective insoluble matrix former	Different processing and supplier base
Methacrylate copolymers	Tunable pH-dependent release	Higher formulation complexity and different regulatory positioning
Polyvinyl alcohol	Useful film-forming and moisture-barrier properties	Not a direct replacement for all sustained-release functions
Lipids and waxes	Low-cost hydrophobic release control	Greater variability and different processing requirements
Hydroxypropyl cellulose	Good binding and film-forming properties	More water-soluble and less suitable for some sustained-release barriers

Ethylcellulose has an advantage when developers need a predictable hydrophobic membrane or matrix and do not require pH-triggered release. Hypromellose is often preferred for straightforward hydrophilic matrix tablets. Methacrylate polymers are stronger competitors in enteric and pH-dependent systems.

What regulatory approvals and quality standards apply to ethylcellulose?

Ethylcellulose is regulated as an excipient rather than as an active pharmaceutical ingredient. It does not receive FDA drug approval independently for each use. Its acceptability depends on the finished product formulation, manufacturing controls, route of administration, specification, and safety assessment.

Key regulatory considerations include:

• United States Pharmacopeia-National Formulary monograph status.
• European Pharmacopoeia monograph status.
• FDA Inactive Ingredient Database entries.
• Food and Drug Administration review of the finished dosage form.
• Residual solvent controls under ICH Q3C.
• Elemental impurity controls under ICH Q3D.
• Good manufacturing practice for excipient production and distribution.
• Change-control and comparability obligations.

FDA Inactive Ingredient Database listings support precedent for use but do not automatically authorize every concentration, route, dosage form, or patient population [4]. A new use may require a safety justification within the drug application.

Does ethylcellulose have FDA Orange Book exclusivity?

No. Ethylcellulose is not an approved drug product with an Orange Book listing. Orange Book patents and exclusivity attach to approved drug products, not to the excipient as a standalone commercial ingredient [5].

A drug product containing ethylcellulose may have Orange Book patents covering:

• The active pharmaceutical ingredient.
• The dosage form.
• A modified-release profile.
• A coating or matrix composition.
• A method of treatment.
• Manufacturing steps.

Those rights protect the finished product and may affect excipient demand indirectly. They do not create exclusivity for ethylcellulose itself.

What patents protect ethylcellulose formulations?

The base polymer is a mature material with extensive prior art. Commercial protection generally resides in formulation and manufacturing claims rather than in broad ownership of ethylcellulose.

Relevant patent categories include:

Patent category	Typical claim subject
Modified-release composition	Drug plus ethylcellulose matrix, pore former, binder, or lubricant
Coated multiparticulates	Core particle and ethylcellulose membrane
Taste-masking formulation	Drug particles coated with ethylcellulose or a polymer blend
Aqueous dispersion	Polymer, plasticizer, surfactant, and processing conditions
Manufacturing method	Spray coating, curing, extrusion, granulation, or drying parameters
Combination polymer system	Ethylcellulose with hypromellose, methacrylate, lipid, or other excipients

Patent strength depends on claim breadth, expiration, validity, enablement, and design-around options. A formulation patent may be commercially relevant to a drug manufacturer but have limited value to an excipient producer unless the producer licenses a proprietary dispersion or platform.

Are there Paragraph IV challenges involving ethylcellulose?

Paragraph IV certifications apply to abbreviated new drug applications for drug products listed in the Orange Book. They do not apply to bulk ethylcellulose.

A generic manufacturer may challenge patents covering an ethylcellulose-based controlled-release product. The resulting litigation can delay or redirect demand for a particular grade, but it does not generally block the sale of ethylcellulose for other formulations.

What manufacturing and supply-chain barriers affect ethylcellulose?

The main barriers are qualification and consistency, not basic chemical synthesis.

Manufacturers must control:

• Degree of ethoxyl substitution.
• Viscosity and molecular-weight distribution.
• Particle morphology and flow.
• Residual solvents.
• Moisture content.
• Ash and inorganic residues.
• Bioburden where relevant.
• Batch-to-batch coating performance.
• Packaging stability and transport conditions.

A pharmaceutical customer may take months or years to qualify a new supplier because a change can affect dissolution, coating weight gain, tablet hardness, stability, and bioequivalence. That creates switching costs and supports incumbent suppliers.

Supply risk remains concentrated in:

• Cellulose feedstock availability.
• Ethanol and chemical reagent costs.
• Energy-intensive drying and processing.
• Regional manufacturing concentration.
• Freight and hazardous-material requirements for solvent-based systems.
• Regulatory scrutiny of manufacturing-site changes.

A second-source strategy is commercially valuable, but qualification of a replacement supplier is not immediate. Suppliers with multiple manufacturing sites, established quality agreements, and global regulatory files have an advantage.

What licensing and partnership opportunities exist in ethylcellulose?

Licensing activity is more likely to involve delivery systems than bulk polymer supply. Commercial arrangements may cover:

• Aqueous dispersion technology.
• Controlled-release coating platforms.
• Pediatric taste-masking systems.
• Contract formulation and process development.
• Regional distribution rights.
• Custom grades for a large pharmaceutical customer.

Bulk ethylcellulose is generally purchased through supply agreements, technical contracts, and distribution arrangements rather than conventional pharmaceutical patent licenses. The strongest partnership opportunities involve proprietary processing, regulatory support, and application-specific formulations.

What litigation risks affect the ethylcellulose market?

The excipient itself is unlikely to generate the litigation profile of an active pharmaceutical ingredient. Litigation risk is concentrated in the finished drug product.

Potential disputes involve:

• Infringement of modified-release formulation patents.
• Trade-secret claims involving coating processes.
• Supplier quality failures.
• Product recalls linked to dissolution or stability.
• Patent settlements between branded and generic drug companies.
• Contract disputes over supply interruption or specification changes.

A patent settlement involving a controlled-release drug can alter the launch date of a generic and temporarily change demand for a particular ethylcellulose grade. It does not usually change the long-term market structure.

What is the competitive outlook for ethylcellulose suppliers?

Competition will separate into two tiers.

The first tier will consist of global suppliers with compendial grades, multinational quality systems, and technical service. These companies can defend pricing through qualification history and regulatory support.

The second tier will consist of regional producers competing mainly on price and availability. Their share should grow where customers can qualify alternate suppliers without extensive reformulation. Their progress will be slower in regulated markets and complex controlled-release products.

The strongest commercial strategy is to sell ethylcellulose as part of a formulation solution. Dry polymer volume alone has limited differentiation. Preformulated dispersions, coating systems, process development, and regulatory documentation create more defensible margins.

What generic launch scenarios could increase ethylcellulose demand?

Generic launches can increase demand through three channels:

1. A generic copies an existing ethylcellulose-based modified-release product.
2. A developer selects ethylcellulose to design around a competitor's formulation.
3. A branded product loses exclusivity and expands the market for lower-cost multiparticulate or controlled-release versions.

The timing of demand depends on patent expiration, regulatory approval, manufacturing scale-up, and bioequivalence success. A patent expiry does not guarantee immediate volume growth because complex generics may require clinical or pharmacokinetic development.

Key Takeaways

• Ethylcellulose is a mature pharmaceutical excipient with stable demand and selective growth opportunities.
• Modified-release tablets and coatings remain the main demand base.
• Aqueous dispersions, taste masking, multiparticulates, and advanced oral delivery offer better growth and margin potential.
• A practical base-case value-growth range is approximately 3% to 7% annually, although no authoritative standalone market dataset exists.
• Pharmaceutical-grade qualification, compendial compliance, and batch consistency create meaningful switching costs.
• The principal competitors are hypromellose, methacrylate copolymers, polyvinyl acetate, polyvinyl alcohol, and lipid-based systems.
• Ethylcellulose has no independent Orange Book exclusivity or Paragraph IV exposure.
• Patent value is concentrated in finished drug formulations, coating systems, and manufacturing processes.
• Supplier economics favor companies offering dispersions, technical support, and regulatory documentation rather than bulk polymer alone.
• Generic modified-release launches are the main potential source of incremental volume.

FAQs

Is ethylcellulose a high-margin pharmaceutical excipient?

Qualified pharmaceutical grades and aqueous dispersions can generate stronger margins than commodity powder. Margin depends on documentation, customer qualification, technical service, and the degree of formulation integration.

Can ethylcellulose be replaced by hypromellose?

Sometimes. Hypromellose is often suitable for hydrophilic matrix tablets, but it is not a universal replacement for ethylcellulose's water-insoluble barrier and diffusion-control properties.

Is ethylcellulose suitable for aqueous film coating?

The polymer itself is water-insoluble, but commercial aqueous dispersions allow it to be applied from water-based coating systems. Process conditions must support particle coalescence and film formation.

Does ethylcellulose have biosimilar exposure?

No direct biosimilar exposure exists because ethylcellulose is a synthetic excipient, not a biologic active ingredient. It can be used in biologic or biosimilar formulations, but its market demand is primarily associated with oral solid dosage forms.

Which ethylcellulose product has the strongest commercial position?

Aqueous, application-ready dispersions generally have stronger commercial defensibility than standard powder because they combine polymer supply with coating performance, technical support, and process know-how.

References

1. United States Pharmacopeial Convention. (2024). Ethylcellulose monograph. In United States Pharmacopeia and National Formulary.

2. European Directorate for the Quality of Medicines & HealthCare. (2024). Ethylcellulose monograph. In European Pharmacopoeia.

3. Colorcon. (n.d.). Surelease aqueous ethylcellulose dispersion. Colorcon product information.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.